deltatrials
Completed PHASE4 NCT00280605

ALF-ONE : ALFuzosin ONcE Daily

Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China

Sponsor: Sanofi

Conditions Prostatic Hyperplasia
Interventions Alfuzosin
Updated 6 times since 2017 Last updated: Aug 30, 2010 Started: Aug 31, 2005 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This PHASE4 trial investigates Prostatic Hyperplasia and is currently completed. Sanofi leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.